Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
aRe2vGnEvEkfKeuB